DongKoo Bio & Pharma Co Ltd

DongKoo Bio & Pharma maintains a debt-to-equity ratio of 0.45, indicating a relatively conservative capital structure with liabilities significantly below equity. The company's liquidity position is assessed as medium, with a current ratio of 1.02, suggesting limited short-term liquidity cushion. Free cash flow is negative at -6.91 billion KRW, driven by capital expenditures of -12.77 billion KRW, which outpace operating cash flow of 6.21 billion KRW.

Profitability metrics show a return on equity of 3.96% and return on assets of 2.09%, both below the typical thresholds for high-margin pharmaceutical firms. These figures suggest the company is generating modest returns relative to its equity and asset base. Gross profit of 39.38 billion KRW represents 61.3% of revenue, but operating income of 4.66 billion KRW and net income of 4.41 billion KRW indicate pressure from operating expenses.

The company's geographic and segment exposure is not disclosed in the available data, but revenue concentration in a single jurisdiction or product line could increase operational risk. No specific segments are identified in the financial snapshot.

Growth trajectory is not explicitly outlined in the data, but the negative free cash flow and high capital expenditures suggest the company is investing in long-term projects. Revenue of 64.21 billion KRW in the latest period provides a baseline for future performance.

Risk factors include a liquidity risk from negative net cash position after subtracting total debt, and a potential dilution risk from the company's capital structure. No dilution sources are explicitly identified in the data, but the low dilution risk score suggests no immediate pressure from share issuance.

Recent events are not detailed in the available data, but the company's financial snapshot indicates ongoing investment in capital expenditures and a focus on maintaining a balanced capital structure.

Dongkoo Bio & Pharma Co Ltd (006620.KQ) has undergone a significant update to its corporate profile, with its primary business activity now formally classified as "Pharmaceuticals" within the broader "Healthcare" economic sector. This taxonomic clarification, previously unrecorded, provides a definitive framework for understanding the company's operational focus and industry alignment. Concurrently, the company's risk assessment metrics have been initialized, revealing a "low" dilution risk and a "medium" liquidity risk. The low dilution risk suggests that shareholders are currently protected from significant equity erosion, while the medium liquidity risk indicates moderate constraints on the ease of trading or converting assets, a factor investors should monitor for potential impact on capital efficiency. These structural updates occur against a backdrop of limited external market engagement, as the company currently reports zero analyst coverage, no index memberships, and no identified top institutional holders. This absence of traditional market validators underscores the importance of the newly established internal risk and classification metrics for stakeholders seeking to evaluate the firm's standing. The combination of clear sector classification and defined risk parameters offers a more transparent view of Dongkoo Bio & Pharma's financial health and strategic positioning. For investors, these changes matter as they establish a baseline for future performance tracking, particularly in assessing how the company manages liquidity within the pharmaceutical sector amidst a lack of analyst scrutiny. [doc:006620.kq-ha-financials]

Net income surged 2,369.7% year-over-year to 50.3 billion KRW, demonstrating exceptional recent profitability growth.

Free cash flow turned positive with a 281.4% increase, reaching 35.4 billion KRW in the latest period.

Revenue grew at an 11.8% compound annual growth rate over the last four years, showing consistent top-line expansion.

Long-term debt increased significantly to 128.8 billion KRW, resulting in a high credit risk flag.

Debt-to-equity ratio of 0.45 is well above the pharmaceutical cohort median of 0.18, indicating higher leverage.

The company faces medium liquidity risk, which could constrain short-term financial flexibility despite recent cash flow improvements.

Revenue KRW 194.99B, +25,7% YoY; Operating income +109,3% YoY.

• ▍Revenue KRW 194.99B, +25,7% YoY
• ▍Operating income +109,3% YoY
• ▍Net income −29,1% YoY
• ▍Free cash flow −120,5% YoY
• ▍Net margin 3.4%

Revenue KRW 155.15B; Operating income KRW 8.14B.

• ▍Revenue KRW 155.15B
• ▍Operating income KRW 8.14B
• ▍Net margin 6.0%